Chen N, Zhou M, Dong X et al. (2020) Epidemiological and clinical characteristics of cases of 2019 novel coronavirus pneumonia in Wuhan: a descriptive study. Lancet 395:207-513
Huag C, Wang Y, Li X et al. (2020) Clinical features of patients infected with 2019 novel corona- virus in Wuhan, China. Lancet 395:497-506
Tang N, Li D, Wang X, Sun Z. (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. ;18(4):844-847 https://doi.org/10.1111/jth.14768
Hao C, Sun M, Wang H, Zhang L et al. (2019) Low Molecular Weight Heparins and Their Clini- cal Applications. Prog Mol Biol Transl Sci163:21-39
Hirsh J, Warkentin TE, Shaughnessy SG, et al. (2001) Heparin and low molecular weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest. 119 (1 Suppl): 64S- 95S
Kalil AC (2020) Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA;323(19):1897–1898. doi:10.1001/jama.2020.4742
Mousavi S, Moradi M, Khorshidahmad T et al. (2015)Anti-inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci:507151. doi:10.1155/2015/507151
Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a re- view of immune changes in patients with viral pneumonia. Emerg Microbes Infec 2020; 9: 727- 732
Johnson Z, Kosco-Vilbois MH, Herren S et al. (2004) Interference with heparin binding and oli- gomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J. Im- munol 173: 5776–5785
Thachil J. The versatile heparin in COVID-19. J. Thromb Haemost. https://doi.org/10.1111/jth.14821
Yang Y, Yang M, Shen C et al. (2020) Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019- nCoV infections. medRxiv. 2020 feb 17;2020.2.11.20021493.
Turpie AGG, Chin BSP, Lip GYH. (2002)Venous thromboembolism: treatment strategies. BMJ 26; 325: 948–950
Tang N, Bay H, Chen X et al. (2020) Anticoagulant treatment is associated with decreased mortal- ity in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18(5):1094- 1099. doi: 10.1111/jth.14817
Holger J. Schünemann, Mary Cushman, Allison E. Burnett American Society of Hematology (2018) guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients Blood Adv. Nov 27; 2(22): 3198–3225.
Lip GYH, Frison L, Halperin JL et al. (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hyper- tension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 57:173– 80
IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.
Kaatz S, Ahmad D, Spyropoulos AC et al. (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13:2119-21
Helms J, Tacquard C, Severac F et al. (2020) High risk of thrombosis in patients in severe SARS- CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 10.1007/s00134- 020-06062-x
Llitjos JF, Leclerc M, Chochois C et al. (2020) High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. Intensive Care Med https://doi.org/10.1007/s00134- 020-06082-7
Varga Z, Flammer AJ, Steiger P et al. (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234): 1417–1418
Bonetti PO, Lerman LO, Lerman A. (2003) Endothelial dysfunction - a marker of atherosclerotic risk. Arterioscl Thromb Vas 23:168–75
Antoniak S. (2018) The coagulation system in host defense. Res Pract Thromb Haemost 2(3):549– 57
Antoniak S, Mackman N. (2014) Multiple roles of the coagulation protease cascade during virus infection. Blood123(17):2605–13
Hwang, D, Chamberlain D, Poutanen S et al. (2005) Pulmonary pathology of severe acute respira- tory syndrome in Toronto. Mod Pathol 18, 1–10 . https://doi.org/10.1038/modpathol.3800247
Lax SF, Skok K, Zechner P, et al. (2020) Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series [published online ahead of print, 2020 May 14]. Ann Intern Med. 2020;M20-2566. doi:10.7326/M20-2566
Casey K, Iteen A, Nicolini R et al. (2020) COVID-19 pneumonia with hemoptysis: Acute seg- mental pulmonary emboli associated with novel coronavirus infection. Am J Emerg Med S0735- 6757(20)30239-4. doi:10.1016/j.ajem.2020.04.011
Luo W, Yu H, Gou J et al. (2020) Clinical Pathology of Critical Patient with Novel Coronavirus Pneumonia (COVID-19). Preprints, 2020020407
Wichmann D, Sperhake J, Lutgehetmann M et al. (2020) Autopsy Findings and Venous Throm- boembolism in patients with COVID-19: A Prospective Cohort Study. Ann Intern Med doi:10.7326/M20-2003
Shastri MD, Stewart N, Horne J et al. (2015) In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin. PLoS One. 11;10(5):e0126763. doi: 10.1371/journal.pone.0126763.
Pons S, Fodil S, Azoulay E, Zafrani L. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care. 2020;24(1):353. Published 2020 Jun 16. doi:10.1186/s13054-020-03062-7
Guang Chen, Di Wu, Wei Guo et al. (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J.Clin. Invest 130(5):2620-2629
Xu X, Han M, Li T, Sun W et al. (2020) Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. Apr 29. doi: 10.1073/pnas.2005615117
Cossette B, Pelletier ME, Carrier N et al. (2010) Evaluation of bleeding risk in patients exposed to therapeutic unfractionated or low-molecular-weight heparin: a cohort study in the context of a quality improvement initiative. Ann Pharmacother 44(6):994-1002. doi: 10.1345/aph.1M615